IBRXImmunityBio,

Each row is one issuer’s token for ImmunityBio,, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of ImmunityBio,, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
IBRX	Robinhood	RBNH	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Type

Common stock

Sector

Healthcare › Biotechnology

Exchange

Nasdaq

Listed since

Mar 10, 2021

Shares outstanding

1.06B

Employees

691

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.